INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Albany Molecular Research Inc.

Glancy Binkow & Goldberg LLP reminds investors of Albany Molecular Research Inc. (“Albany Molecular” or the “Company”) (NASDAQ:AMRI) that purchasers of Albany Molecular common stock between August 5, 2014 and November 5, 2014, inclusive (the “Class Period”), have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit

Albany Molecular is a contract research and manufacturing company that provides integrated drug discovery, development and manufacturing services primarily in the United States, Europe and Asia. The Complaint, filed in the United States District Court for the Eastern District of New York, alleges that throughout the Class Period defendants issued materially false and misleading statements about the Company's operations, financial performance and prospects, including statements issued by Albany Molecular concerning the Company’s financial guidance and operations at its OsoBio facility.

On November 5, 2014, Albany Molecular announced weak financial and operating results for third quarter 2014, including an $8.6 million loss in the quarter. The Company attributed these results to a “confluence of a business interruption event at our OsoBio facility, together with lower Discovery and API revenue.” In addition, the Company disclosed a “weather-related power interruption at our OsoBio facility in Albuquerque took the facility offline for a period of time, contributing to the loss of finished product and the need to remediate one of the suites at the facility.” Following this news, Albany Molecular stock declined nearly 27%, or $6.08 per share, to close at $16.59 per share on November 5, 2014.

If you are a member of the Class described above, you may move the Court no later than January 12, 2015, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, or Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.